EGFR antibody (Extracellular Domain) (FITC)

Catalog No. ABIN181808

Product Details anti-EGFR Antibody (FITC)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Binding Specificity: Extracellular Domain

Reactivity: Human

Host: Rat

Clonality: Monoclonal

Conjugate: This EGFR antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Specificity: This antibody recognises the Epidermal Growth Factor Receptor (EGF-R), which is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas. High level expression of EGFR is often associated with advanced disease and poor prognosis. The antibody binds to epitope B from EGFR (1,2).Aff. Const.:6.7 x 10e-9 M

Purification: Ion Exchange Chromatography.

Immunogen: Extracellular domain of human EGF-receptor from head and neck carcinoma

Clone: ICR10

Isotype: IgG2a

Application Details

Application Notes: Flow Cytometry: Use 10 μL of 1/10 diluted antibody to label 10^6 cells in 100 μL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, pH 7.4 containing 0.09 % Sodium Azide as preservative and 1 % BSA as stabilizer.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing. Dilute only prior to immediate use

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Alternative Name: EGFR / ERBB1 (EGFR Products)

Background: EGF Receptor (EGFR) and erbB2, erbB3, and ErbB4 are members of subclass I of receptor tyrosine kinases. EGFR/erbB receptors are activated upon binding of EGF and EGF-related growth factors such as TGF alpha, beta-cellulin, Hb-EGF, HRG, or NRG. Binding of these ligands leads to receptor homo- and heterodimerization followed by autophosphorylation and activation of downstream signal transduction pathways (MAPK, PI3K/PKB, and STAT). In addition, EGFR becomes fully activated after phosphorylation of Y845 by src family kinases. Phosphorylation of Y1045 leads to association with cbl and subsequent receptor degradation. Phosphorylation of S1047 by CamKinase II leads to attenuation of kinase activity, phosphorylation of T654 (by PKC) and T669 (by MAPK, p38) interferes with receptor endocytosis/recycling.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

Gene ID: 1956

NCBI Accession: NP_005219

UniProt: P00533

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins